Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates [Yahoo! Finance]
Vaxxinity, Inc. (VAXX)
Company Research
Source: Yahoo! Finance
of immunotherapeutic vaccines, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update. “2024 will prove to be a critical year for Vaxxinity as we refocus our efforts on our neurodegeneration programs and move closer to obtaining our company's first approval,” said Mei Mei Hu, CEO of Vaxxinity. “Just this month, we presented exploratory biomarker data from our Phase 1 trial of UB-312 in Parkinson's patients: a first of its kind demonstrating target engagement of toxic alpha-synuclein in the CNS and a potential correlation with clinical efficacy. This represents a major step for our platform in neurodegeneration where the safe engagement of aberrant protein targets in the CNS remains critical, and new hope for the Parkinson's community. We also seek to advance UB-311, our anti-Aß Alzheimer's candidate, as we resume dialogue with regulatory authorities and partners. Finally, we're looking forward to the readout fro
Show less
Read more
Impact Snapshot
Event Time:
VAXX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VAXX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VAXX alerts
High impacting Vaxxinity, Inc. news events
Weekly update
A roundup of the hottest topics
VAXX
News
- Vaxxinity Issues Shareholder Letter [Yahoo! Finance]Yahoo! Finance
- Vaxxinity Issues Shareholder LetterGlobeNewswire
- Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock [Yahoo! Finance]Yahoo! Finance
- Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common StockGlobeNewswire
- Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
VAXX
Earnings
- 3/27/24 - Beat
VAXX
Sec Filings
- 5/3/24 - Form EFFECT
- 4/30/24 - Form S-8
- 4/30/24 - Form S-8
- VAXX's page on the SEC website